MY187655A - Use of nucleosome-transcription factor complexes for cancer detection - Google Patents
Use of nucleosome-transcription factor complexes for cancer detectionInfo
- Publication number
- MY187655A MY187655A MYPI2018703273A MYPI2018703273A MY187655A MY 187655 A MY187655 A MY 187655A MY PI2018703273 A MYPI2018703273 A MY PI2018703273A MY PI2018703273 A MYPI2018703273 A MY PI2018703273A MY 187655 A MY187655 A MY 187655A
- Authority
- MY
- Malaysia
- Prior art keywords
- transcription factor
- nucleosome
- cancer detection
- factor complexes
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1604806.8A GB201604806D0 (en) | 2016-03-22 | 2016-03-22 | Method of identifying a cancer of unknown origin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY187655A true MY187655A (en) | 2021-10-07 |
Family
ID=55968658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018703273A MY187655A (en) | 2016-03-22 | 2017-03-22 | Use of nucleosome-transcription factor complexes for cancer detection |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200363418A1 (enExample) |
| EP (3) | EP4270007A3 (enExample) |
| JP (1) | JP6777757B2 (enExample) |
| KR (2) | KR102369544B1 (enExample) |
| CN (1) | CN109313192B (enExample) |
| AU (1) | AU2017238442A1 (enExample) |
| CA (1) | CA3018428C (enExample) |
| ES (2) | ES2861440T5 (enExample) |
| GB (1) | GB201604806D0 (enExample) |
| MY (1) | MY187655A (enExample) |
| SG (1) | SG11201807991QA (enExample) |
| WO (1) | WO2017162755A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
| TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| TW202242130A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
| US20240318259A1 (en) * | 2021-09-24 | 2024-09-26 | Oncocross Co., Ltd. | Method for determining primary tumor site |
| TW202530419A (zh) | 2023-10-04 | 2025-08-01 | 比利時商比利時意志有限公司 | Pcr方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274861B1 (en) * | 2000-03-27 | 2009-12-23 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells |
| WO2003025583A2 (en) * | 2001-09-14 | 2003-03-27 | F. Hoffmann-La Roche Ag | Differential diagnosis of disorders of iron metabolism |
| US7248921B2 (en) * | 2003-06-02 | 2007-07-24 | Cameron Health, Inc. | Method and devices for performing cardiac waveform appraisal |
| US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| US20040236188A1 (en) * | 2003-05-19 | 2004-11-25 | Ge Medical Systems Information | Method and apparatus for monitoring using a mathematical model |
| US8029989B2 (en) * | 2005-08-26 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Method using snail transcriptional repressor |
| US20090298097A1 (en) * | 2007-07-17 | 2009-12-03 | Harris Pamela J | Methods for the diagnosis of lung cancer |
| WO2010001933A1 (ja) * | 2008-07-01 | 2010-01-07 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
| MY148542A (en) * | 2009-06-15 | 2013-04-30 | Cancer Res Initiatives Foundation | A method for the assessment of cancer in a biological sample obtained from a subject |
| EP2270510A1 (en) * | 2009-07-02 | 2011-01-05 | EMBL (European Molecular Biology Laboratory) | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| GB201115095D0 (en) * | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| JP6263474B2 (ja) * | 2011-12-07 | 2018-01-17 | シンガポール ボリション ピーティーイー リミテッド | ヌクレオソームアダクト検出法 |
| GB201303576D0 (en) * | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
-
2016
- 2016-03-22 GB GBGB1604806.8A patent/GB201604806D0/en not_active Ceased
-
2017
- 2017-03-22 MY MYPI2018703273A patent/MY187655A/en unknown
- 2017-03-22 KR KR1020217012412A patent/KR102369544B1/ko not_active Expired - Fee Related
- 2017-03-22 KR KR1020187029952A patent/KR102246699B1/ko not_active Expired - Fee Related
- 2017-03-22 AU AU2017238442A patent/AU2017238442A1/en not_active Abandoned
- 2017-03-22 WO PCT/EP2017/056851 patent/WO2017162755A1/en not_active Ceased
- 2017-03-22 US US16/087,060 patent/US20200363418A1/en not_active Abandoned
- 2017-03-22 EP EP23177260.9A patent/EP4270007A3/en not_active Withdrawn
- 2017-03-22 JP JP2018549812A patent/JP6777757B2/ja active Active
- 2017-03-22 SG SG11201807991QA patent/SG11201807991QA/en unknown
- 2017-03-22 EP EP17712782.6A patent/EP3433616B2/en active Active
- 2017-03-22 ES ES17712782T patent/ES2861440T5/es active Active
- 2017-03-22 CN CN201780031827.0A patent/CN109313192B/zh not_active Expired - Fee Related
- 2017-03-22 CA CA3018428A patent/CA3018428C/en active Active
- 2017-03-22 ES ES20210821T patent/ES2951136T3/es active Active
- 2017-03-22 EP EP20210821.3A patent/EP3839513B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3433616B2 (en) | 2024-07-24 |
| ES2861440T3 (es) | 2021-10-06 |
| EP4270007A3 (en) | 2023-12-20 |
| US20200363418A1 (en) | 2020-11-19 |
| GB201604806D0 (en) | 2016-05-04 |
| KR102369544B1 (ko) | 2022-03-03 |
| CA3018428A1 (en) | 2017-09-28 |
| CA3018428C (en) | 2024-03-19 |
| EP3839513B1 (en) | 2023-06-14 |
| CN109313192A (zh) | 2019-02-05 |
| EP3839513C0 (en) | 2023-06-14 |
| EP3433616A1 (en) | 2019-01-30 |
| JP2019510974A (ja) | 2019-04-18 |
| EP3433616B1 (en) | 2020-12-30 |
| KR102246699B1 (ko) | 2021-05-04 |
| SG11201807991QA (en) | 2018-10-30 |
| EP3839513A1 (en) | 2021-06-23 |
| KR20190013707A (ko) | 2019-02-11 |
| AU2017238442A1 (en) | 2018-10-11 |
| CN109313192B (zh) | 2022-07-26 |
| KR20210049954A (ko) | 2021-05-06 |
| EP4270007A2 (en) | 2023-11-01 |
| WO2017162755A1 (en) | 2017-09-28 |
| ES2861440T5 (en) | 2025-02-05 |
| JP6777757B2 (ja) | 2020-10-28 |
| ES2951136T3 (es) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| GB201305223D0 (en) | Reflection detection type measurement apparatus for skin autofluorescence | |
| MA39776A (fr) | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| AU2017260630A1 (en) | Detection of lung neoplasia by analysis of methylated DNA | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| BR112015008255A2 (pt) | método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata | |
| MX2014003832A (es) | Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo. | |
| TN2013000358A1 (en) | Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects | |
| EP2971132A4 (en) | FABRIC AND BLOOD-BASED MIRNA BIOMARKERS FOR THE DIAGNOSIS, FORECASTING AND PREDICTING THE METASTAS POTENTIAL IN COLOR LECTAL CANCER | |
| GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| MY192513A (en) | Compositions and methods related to diagnosis of prostate cancer | |
| EP4513187A3 (en) | Methods of detecting prostate cancer | |
| MX360236B (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| EP3690063A3 (en) | Diagnosis of lung cancer | |
| WO2013106747A3 (en) | Methods and compositions for the treatment and diagnosis of thyroid cancer | |
| WO2014124339A3 (en) | Use of translational profiling to identify target molecules for therapeutic treatment | |
| EP4270007A3 (en) | Use of dna-transcription factor complexes for cancer detection | |
| IN2015DN01646A (enExample) | ||
| MA40636A (fr) | Procédés pour détecter le cancer de la prostate | |
| MX2016002529A (es) | Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica. | |
| MX376087B (es) | Inhibidores macrocíclicos de cinasa rip2. | |
| AU2012371260A8 (en) | Predicitive biomarker for cancer treatment with ADCC enhanced antibodies |